Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 20/20 | 0.47 |
| ▸ | PKD1 | P98161 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26684106 | 1.00 | MAP3K14 (0.47) | MAP3K14PKD1 | |
| SCHEMBL30667979 | 1.00 | MAP3K14 (0.47) | MAP3K14PKD1 | |
| SCHEMBL26683985 | 0.94 | MAP3K14 (0.46) | MAP3K14PKD1 | |
| SCHEMBL26683990 | 0.94 | MAP3K14 (0.46) | MAP3K14PKD1 | |
| SCHEMBL26684200 | 0.92 | MAP3K14 (0.41) | MAP3K14PKD1 | |
| SCHEMBL26684516 | 0.90 | MAP3K14 (0.39) | MAP3K14PKD1 | |
| SCHEMBL30668059 | 0.90 | MAP3K14 (0.39) | MAP3K14PKD1 | |
| SCHEMBL26684525 | 0.90 | MAP3K14 (0.39) | MAP3K14PKD1 | |
| SCHEMBL30667927 | 0.90 | MAP3K14 (0.49) | MAP3K14PKD1 | |
| SCHEMBL26684449 | 0.90 | MAP3K14 (0.59) | MAP3K14PKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| WO-2023217906-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023217906-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | MAP3K14 94/4885PKD1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.